SwePub
Sök i LIBRIS databas

  Extended search

onr:"swepub:oai:DiVA.org:liu-150237"
 

Search: onr:"swepub:oai:DiVA.org:liu-150237" > Perspectives for pe...

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist
  • Lange, C.Karolinska Institutet,Res Ctr Borstel, Germany; German Ctr Infect Res DZIF, Germany; Univ Lubeck, Germany; Karolinska Inst, Sweden (author)

Perspectives for personalized therapy for patients with multidrug-resistant tuberculosis

  • Article/chapterEnglish2018

Publisher, publication year, extent ...

  • 2018-07-11
  • WILEY,2018
  • printrdacarrier

Numbers

  • LIBRIS-ID:oai:DiVA.org:liu-150237
  • https://urn.kb.se/resolve?urn=urn:nbn:se:liu:diva-150237URI
  • https://doi.org/10.1111/joim.12780DOI
  • http://kipublications.ki.se/Default.aspx?queryparsed=id:138790729URI

Supplementary language notes

  • Language:English
  • Summary in:English

Part of subdatabase

Classification

  • Subject category:ref swepub-contenttype
  • Subject category:for swepub-publicationtype

Notes

  • Funding Agencies|German Center for Infection Research (DZIF); Swedish Research council; Swedish Heart and Lung Foundation (Oscar II Jubilee Foundation); South African National Research Foundation; Leibniz Research Campus EvoLung
  • According to the World Health Organization (WHO), tuberculosis is the leading cause of death attributed to a single microbial pathogen worldwide. In addition to the large number of patients affected by tuberculosis, the emergence of Mycobacterium tuberculosis drug-resistance is complicating tuberculosis control in many high-burden countries. During the past 5years, the global number of patients identified with multidrug-resistant tuberculosis (MDR-TB), defined as bacillary resistance at least against rifampicin and isoniazid, the two most active drugs in a treatment regimen, has increased by more than 20% annually. Today we experience a historical peak in the number of patients affected by MDR-TB. The management of MDR-TB is characterized by delayed diagnosis, uncertainty of the extent of bacillary drug-resistance, imprecise standardized drug regimens and dosages, very long duration of therapy and high frequency of adverse events which all translate into a poor prognosis for many of the affected patients. Major scientific and technological advances in recent years provide new perspectives through treatment regimens tailor-made to individual needs. Where available, such personalized treatment has major implications on the treatment outcomes of patients with MDR-TB. The challenge now is to bring these adances to those patients that need them most.

Subject headings and genre

Added entries (persons, corporate bodies, meetings, titles ...)

  • Alghamdi, W. A.Univ Florida, FL USA (author)
  • Al-Shaer, M. H.Univ Florida, FL USA,German Ctr Infect Res DZIF, Germany; Res Ctr Borstel, Germany,Natl Reference Ctr Mycobacteria, Germany (author)
  • Brighenti, S.Karolinska Institutet,Karolinska Univ Hosp Huddinge, Sweden (author)
  • Diacon, A. H.Task Appl Sci, South Africa; Stellenbosch Univ, South Africa (author)
  • DiNardo, A. R.Baylor Coll Med, TX 77030 USA (author)
  • Grobbel, H. P.Res Ctr Borstel, Germany; German Ctr Infect Res DZIF, Germany; Univ Lubeck, Germany (author)
  • Groschel, M. I.Univ Groningen, Netherlands; Natl Reference Ctr Mycobacteria, Germany (author)
  • von Groote-Bidlingmaier, F.Task Appl Sci, South Africa (author)
  • Hauptmann, M.German Ctr Infect Res DZIF, Germany; Res Ctr Borstel, Germany (author)
  • Heyckendorf, J.Res Ctr Borstel, Germany; German Ctr Infect Res DZIF, Germany; Univ Lubeck, Germany (author)
  • Kohler, N.Res Ctr Borstel, Germany; German Ctr Infect Res DZIF, Germany; Univ Lubeck, Germany (author)
  • Kohl, T. A.Natl Reference Ctr Mycobacteria, Germany,Bernhard Nocht Inst Trop Med, Germany (author)
  • Merker, M.Natl Reference Ctr Mycobacteria, Germany,Res Ctr Borstel, Germany; German Ctr Infect Res DZIF, Germany; Univ Lubeck, Germany (author)
  • Niemann, S.German Ctr Infect Res DZIF, Germany; Natl Reference Ctr Mycobacteria, Germany (author)
  • Peloquin, C. A.Univ Florida, FL USA (author)
  • Reimann, M.Res Ctr Borstel, Germany; German Ctr Infect Res DZIF, Germany; Univ Lubeck, Germany (author)
  • Schaible, U. E.German Ctr Infect Res DZIF, Germany; Res Ctr Borstel, Germany; Univ Lubeck, Germany; LRA INFECTIONS 21, Germany (author)
  • Schaub, D.Res Ctr Borstel, Germany; German Ctr Infect Res DZIF, Germany; Univ Lubeck, Germany (author)
  • Schleusener, V.Natl Reference Ctr Mycobacteria, Germany (author)
  • Thye, T.Bernhard Nocht Inst Trop Med, Germany (author)
  • Schön, ThomasLinköpings universitet,Avdelningen för mikrobiologi och molekylär medicin,Medicinska fakulteten,Department of Clinical Microbiology and Infectious Diseases, Kalmar County Hospital(Swepub:liu)thosc49 (author)
  • Karolinska InstitutetRes Ctr Borstel, Germany; German Ctr Infect Res DZIF, Germany; Univ Lubeck, Germany; Karolinska Inst, Sweden (creator_code:org_t)

Related titles

  • In:Journal of Internal Medicine: WILEY284:2, s. 163-1880954-68201365-2796

Internet link

Find in a library

To the university's database

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Close

Copy and save the link in order to return to this view